Monthly Archives: May 2012

 

RedHill Migraine Trial Successful

May 29, 2012  |  Comments are closed
RedHill Biopharma Ltd. (TASE: RDHL) announced positive results in a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. RedHill has exclusive world-wide rights and is developing RHB-103 with its Canadian co-development partner IntelGenx, Corp. (TSX: IGX ; OTCBB: IGXT). Analysis...
Read more

GE Healthcare Invests $27.5 M in Insightec

May 29, 2012  |  Comments are closed
Elbit Medical Technologies Ltd. (TASE: EMTC) announced that its subsidiary InSightec Image Guided Treatment Ltd. has signed a memorandum of understanding with GE Healthcare. Under the agreement, GE Healthcare will invest $27.5 million in the company. Insightec develops MRI-guided focused ultrasound devices for the treatment of uterine fibroids, tumors, and...
Read more

Avraham Starts Phase 2 MCI

May 17, 2012  |  Comments are closed
Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel. In...
Read more

CollPlant Wound Trial Interim Results

May 10, 2012  |  Comments are closed
CollPlant Holdings Ltd. (TASE: CLPT) reported successful interim results in a preclinical (animal) trial its VergenixFG wound dressing gel made of pure recombinant human collagen, for the treatment of skin lesions. The trial found that the product was effective and had statistically significant better results than corresponding products on the...
Read more

BrainStorm to do MS Stem Cell Study

May 10, 2012  |  Comments are closed
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and the Company is working to advance...
Read more

Rosetta Genomics Gets Cancer Diagnostic Patent

May 10, 2012  |  Comments are closed
Rosetta Genomics, Ltd. (NASDAQ: ROSG) has received a patent allowance from the U.S. Patent and Trademark Office (“USPTO”) for Patent Application 12/800,556 titled, “MICRORNAS AND USES THEREOF.” The allowed claims cover the composition of matter for miR-378, a core element of Rosetta Genomics’ microRNA technology used in its miRview(R) mets...
Read more

Brainsway: Positive Depression Trial Results

May 10, 2012  |  Comments are closed
Brainsway Ltd. (TASE:BRIN) announced positive results from its double-blind multicenter clinical trial for the assessment of the safety and efficacy of Deep Transcranial Magnetic Stimulation (“Deep TMS”) with the Company’s device (the “H-Coil”) in the treatment of major depression. Based on a U.S. Food and Drug Administration (“FDA”) approved clinical...
Read more

InspireMD Completing Stent Trial

May 10, 2012  |  Comments are closed
InspireMD, Inc. (OTC BB: NSPR) announced that the 313th patient has been enrolled in the MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial. The trial is scheduled to enroll 432 patients in total and the Company is on track to release preliminary top line results in the third quarter of...
Read more

Protalix Gets FDA Approval

May 10, 2012  |  Comments are closed
Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. ELELYSO is the first FDA-approved...
Read more

D-Pharm Gets $1M from Chinese Partner

May 10, 2012  |  Comments are closed
D-Pharm Ltd., (TASE: DPRM) has received the first payment of $1M from Jiangsu NHWA Pharmaceutical Co., Ltd. (NHWA) in relation to DP-VPA development for epilepsy in China. NHWA is the leading Chinese company developing and marketing drugs to treat CNS disorders in China. DP-VPA is a novel drug discovered and...
Read more

cCam Raises $3 M

May 9, 2012  |  Comments are closed
cCam Medical Ltd. has raised $3 million from Pontifax Ltd. and Mori Arkin’s Arkin Holdings Ltd. $2.5 million will be transferred at the signing and the balance in milestone payments. cCam also extended its cooperation agreement with Hoffmann-La Roche, which has the right to commercialize the company’s technology in exchange...
Read more